Boston Professional Events List

Live Webinar Process Validation General Principles

Sep 23, 2019 - 01:00 PM - 03:00 PM
WCS Consulting Inc.3190 Stirling Rd, Unit K4 ,Hollywood, FL 33021,

ZIP: 33021
Phone: 844-267-7299 | 954-947-5671  


In 2001 the FDA announced that it would:

• Adopt a Quality Systems model
• Develop Quality Systems guidance
• Implement Risk-Based management plan
• Practice science-based regulation of product quality

This was the beginning of a transition that continues. The FDA guidance and expectations related to process validation are a significant part of the movement to a Quality System approach to compliance.
In the same year, ICH published ICH Q7A which, with the introduction of the term “Quality Management”, signaled the beginning of the transition (Note; ICH Q7 has been updated recently.) Since 2005 ICH has released four guidance documents: ICH Q8, Pharmaceutical Development, ICH Q9, Quality Risk Management, ICH Q10, Pharmaceutical Quality System, ICH Q11, Development and Manufacture of Drug Substances, In 2011, the FDA released the final version of its guidance on Process Validation; Process Validation: General Principles and Practices. Since that time, the European Union published a draft of its Guideline on Process Validation, which has been absorbed into Annex 15, Qualification and Validation. None of these guidance documents are stand-alone. They are interdependent and each heavily references the others. Therefore, it is important that individuals in all areas of the pharmaceutical firm that are involved with any part of the product lifecycle be aware of these guidances and understand how they relate to one another.

In this live training webinar we will discuss the ICH guidance documents, US inspectional guidance and how they relate to and impact the US and EU guidance on process validation. At the core of these guidance documents is ICH Q10, Pharmaceutical Quality System. It establishes the concept of product lifecycle. Although ICH Q8, Pharmaceutical Development, focuses on the product/process development phase of the lifecycle, it includes activities found throughout the product lifecycle. ICH Q9, Quality Risk Management, advocates the application of risk evaluation and management through all stages of product lifecycle. ICH Q11, Development and Manufacture of Drug Substances, combines the elements found in QCH Q8, Q9 and Q10 and applies them to a specific process, the development of a drug substance.

Finally, we will discuss a recent FDA guidance Quality Metrics, and how it will increase the visibility of each pharmaceutical firm’s validation program to the FDA and how the requirements driven by the Quality Metrics program can be integrated into the firm’s validation program and other quality systems.


Who should attend:
The following individuals or disciplines will benefit from attending this Webinar:

  • Senior management

  • Production management

  • Quality management

  • Quality Assurance

  • Quality Assurance Product Reviewers

  • Regulatory

Speaker Details


John G. (Jerry) Lanese is an independent consultant with a focus on Quality Systems and the components of an effective Quality System.

 Wcs Seminars
Registration Details
(Contact us : 844-267-7299 | 954-947-5671  
Don't wait. Register TODAY or  Email  US [email protected]

Event Categories
Keywords: pharmaceutical


Events Calendar

1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 1 2 3 4 5


VIP Life Time Subscription to our Newsletters!